New technologies toward dendritic cell-based cancer immunotherapies

Journal of Dermatology

Volumn 26, Issue 11, 1999, Pages 757-763

  Matsue, Hiroyuki ^a   Morita, Akimichi ^b   Matsue, Keiko ^a   Takashima, Akira ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

Dendritic cells; Langerhans cells; New technology; Tumor vaccine

Indexed keywords

CANCER VACCINE;

ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; DENDRITIC CELL; HOST RESISTANCE; HUMAN; IMMUNOMODULATION; LANGERHANS CELL; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION;

EID: 0033376065     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1346-8138.1999.tb02088.x     Document Type: Article

References (38)

1. Banchereau J, Steinman RM: Dendritic cells and the control of immunity, Nature, 392: 245, 1998.
2. Steinman RM: The dendritic cell system and its role in immunogenicity, Ann Rev Immunol, 9: 271-296, 1991.
3. Bhardwaj N: Interactions of viruses with dendritic cells: A double-edged sword, J Exp Med, 186: 795-799, 1997.
4. Johnson LL, Sayles PC: Interleukin-12, dendritic cells, and the initiation of host-protective mechanisms against Toxoplasma gondii, J Exp Med, 186: 1799-1802, 1997.
5. Shurin MR: Dendritic cells presenting tumor antigen, Cancer Immunol Immunoth, 43: 158-164, 1996.
6. Colaco C: Why are dendritic cells central to cancer immunotherapy?, Molecular Medicine Today, 5: 14-17, 1999.
7. Lotze MT, Farhood H, Wilson CC, Storkus WJ: Dendritic cell therapy of cancer and HIV infection, in Lotze MT, Thomson AW (eds): Dendritic Cells: Biology and Clinical Applications, Academic Press, San Diego, 1999, pp 459-485.
8. Ockert D, Schmitz M, Hampl M, Reiber EP: Advances in cancer immunotherapy, Immunol Today, 20: 63-65, 1999.
9. Nestle FO, Burg G, Dummer R: New perspectives on immunobiology and immunotherapy of melanoma, Immunol Today, 20: 5-7, 1999.
10. van Schooten WC, Strang G, Palathumpat V: Biological properties of dendritic cells: Implications to their use in the treatment of cancer, Mol Med Today, 3: 254-260, 1997.
11. Schuler G, Thurner B, Romani N: Dendritic cells: From ignored cells to major players in T-cell-mediated immunity, Int Arch Allergy Immunol, 112: 317-322, 1997.
12. Steinman RM: Dendritic cells and immune-based therapies, Exp Hematol, 24: 859-862, 1996.
13. Grabbe S, Beissert S, Schwarz T, Granstein RD: Dendritic cells as initiators of tumor immune responses: A possible strategy for tumor immunotherapy?, Immunol Today, 16: 117-121, 1995.
14. Schuler G, Steinman RM: Dendritic cells as adjuvants for immune-mediated resistance to tumors, J Exp Med, 186: 1183-1187, 1997.
15. Shimizu J, Yoshioka T, Kosugi A, Fujiwara H, Hamaoka T: Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells, J Immunol, 142: 1053-1059, 1989.
16. Grabbe S, Bruvers S, Gallo RL, Knisely TL, Nazareno R, Granstein RD: Tumor antigen presentation by murine epidermal cells, J Immunol, 146: 3656-3661, 1991.
17. Inaba K, Metlay JP, Growley MT, Steinman RM: Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ, J Exp Med, 172: 631-640, 1990.
18. Paglia P, Chiodoni G, Rodolfo M, Colombo MP: Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo, J Exp Med, 183: 317-322, 1996.
19. Van Pel A, Van Der Bruggen P, Coulie PG, et al: Genes coding for tumor antigens recognized by cytolytic T lymphocytes, Immunol Rev, 145: 229-250, 1995.
20. Mayordomo JI, Zorina T, Storkus WJ, et al: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity, Nature Med, 1: 1297-1302, 1995.
21. Porgador A, Gilboa E: Bone marrow-generated dendritic cells pulsed with a class 1-restricted peptide are potent inducers of cytotoxic T lymphocytes, J Exp Med, 182: 255-260, 1995.
22. Zitvogel L, Mayordomo JI, Tjandrawan T, et al: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines, J Exp Med, 183: 87-97, 1996.
23. Mayordomo JI, Loftus DJ, Sakamoto H, et al: Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines, J Exp Med, 183: 1357-1365, 1996.
24. Savill JS, Wyllie AH, Henson JE, Walport MJ, Henson PM, Haslett C: Macrophage phagocytosis of aging neutrophils in inflammation cell death in the neutrophil leads to its recognition by macrophages, J Clin Invest, 83: 865-875, 1989.
25. Fadok VA, Savill JS, Haslett C, et al: Different populations of macrophages use either the vitronectin receptor or the phosphatidylserine receptor to recognize and remove apoptotic cells, J Immunol, 149: 4029-4035, 1992.
26. Devitt A, Moffatt OD, Raykundalia C, Capra JD, Simmons DL, Gregory CD: Human CD14 mediates recognition and phagocytosis of apoptotic cells, Nature, 392: 505-509, 1998.
27. 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes, J Exp Med, 188: 1359-1368, 1998.
28. Albert ML, Sauter B, Bhardwaj N: Dendritic cells acquire antigen from apoptotic cells and induce class 1-restricted CTLs, Nature, 392: 86-89, 1998.
29. Zitvogel L, Regnault A, Lozier A, et al: Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes, Nature Med, 4: 594-600, 1998.
30. Gong J, Chen D, Kashiwaba M, Kufe D: Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells, Nature Med, 3: 558-561, 1997.
31. Gong J, Chen D, Kashiwaba M, et al: Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells, Proc Natl Acad Sci USA, 95: 6279-6283, 1998.
32. Boczkowski D, Nair SK, Snyder D, Gilboa E: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo, J Exp Med, 184: 465-472, 1996.
33. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E: Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors, J Exp Med, 186: 1177-1182, 1997.
34. Song W, Kong H-L, Carpenter H, et al: Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity, J Exp Med, 186: 1247-1256, 1997.
35. Specht JM, Wang G, Do MT, et al: Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases, J Exp Med, 186: 1213-1221, 1997.
36. Condon C, Watkins SC, Celluzzi C-M, Thompson K, Falo LD Jr: DNA-based immunization by in vivo transfection of dendritic cells, Nature Med, 2: 1122-1128, 1996.
37. Hsu FJ, Benike C, Fagnoni F, et al: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells, Nature Med, 2: 52-58, 1996.
38. Nestle FO, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells, Nature Med, 4: 328-332, 1998.